Pharmaceuticals Australia

Australia Orphan Drugs Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Australia Orphan Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Type, Therapy Area, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $2.82 Bn Placeholder estimate
Estimate 2025 $3.17 Bn 1.4% of the global market
Projected 2034 $8.92 Bn 181.8% Adds $5.76 Bn over 9 forecast years
CAGR 2025–2034 12.2% Faster than 64% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Australia is 1.35% of the global market.
  • In APAC, the largest is China at $21.52 Bn.
  • Fastest growing: India at 14.1% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$5.76 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Orphan Drugs Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $2.82 Bn — —
2025 (base) $3.17 Bn +$344.3 Mn —
2026 (forecast) $3.55 Bn +$386.4 Mn +12.2%
2027 (forecast) $3.99 Bn +$433.5 Mn +25.9%
2028 (forecast) $4.47 Bn +$486.4 Mn +41.2%
2029 (forecast) $5.02 Bn +$545.7 Mn +58.5%
2030 (forecast) $5.63 Bn +$612.3 Mn +77.8%
2031 (forecast) $6.32 Bn +$687.0 Mn +99.5%
2032 (forecast) $7.09 Bn +$770.8 Mn +123.8%
2033 (forecast) $7.95 Bn +$864.8 Mn +151.2%
2034 (forecast) $8.92 Bn +$970.4 Mn +181.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $234.10 Bn
  2. North America $116.72 Bn
  3. US $102.29 Bn
  4. APAC $53.12 Bn
  5. Europe $40.44 Bn
  6. China $21.52 Bn
  7. Canada $16.67 Bn
  8. Japan $14.59 Bn
  9. Latin America $9.45 Bn
  10. Middle East $8.57 Bn
  11. Germany $7.97 Bn
  12. France $7.08 Bn
  13. Italy $6.24 Bn
  14. Brazil $6.34 Bn
  15. UK $5.66 Bn
  16. Ecuador $4.79 Bn
  17. India $4.61 Bn
  18. Saudi Arabia $4.20 Bn
  19. Africa $4.15 Bn
  20. Spain $3.95 Bn
  21. Mexico $3.35 Bn
  22. Australia (this report) $3.17 Bn
  23. New Zealand $2.45 Bn
  24. Russia $2.18 Bn
  25. South Africa $1.41 Bn
  26. UAE $1.09 Bn
  27. Egypt $762.7 Mn
  28. Philippines $463.3 Mn
  29. Malaysia $357.3 Mn
  30. Hong Kong $360.4 Mn
  31. Thailand $296.9 Mn
  32. Singapore $298.5 Mn
  33. Kenya $145.6 Mn

Report snapshot

Australia Orphan Drugs Market Analysis at a glance
Market size, 2025$3.17 Bn placeholder estimate
Forecast, 2034$8.92 Bn placeholder estimate
Growth (CAGR), 2025–203412.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug type, therapy area and end user (see all)
Key playersNovartis AG, Sanofi, Roche, Takeda Pharmaceutical Company Ltd, Vertex Pharmaceuticals and 1 more (see all)
Regulator in AustraliaTGASource: Therapeutic Goods Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia Orphan Drugs Market Analysis Executive Summary

Orphan drugs treat rare diseases that affect small numbers of people, and get special incentives to encourage development.

Key segments of the orphan Drugs market include drug type (Biologics, Small Molecules and Gene and Cell Therapies) and therapy area (Oncology, Hematology and Neurology).

Bar chart: Australia Orphan Drugs market size, 2024–2034, placeholder estimates. $2.82 Bn in 2024, $3.17 Bn in 2025 and $8.92 Bn in 2034, 12.2% CAGR.
Australia Orphan Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia Orphan Drugs Market Dynamics

Market Growth Drivers

Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the orphan Drugs market. More countries now have national rare disease plans.

Opportunity

Newborn genome screening, gene therapies and access programmes in emerging markets give the orphan Drugs market strong growth.

Market Restraints

Very small patient numbers, long diagnosis delays, high treatment prices and limited specialist centres hold back the orphan Drugs market.

Competitive Landscape for Orphan Drugs Market in Australia

The orphan Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Orphan Drugs Market in Australia

Orphan Drugs in Australia: rules and payment

Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.⁠[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[2]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for orphan Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Orphan Drugs right now, from free public sources.

Latest research 435 papers since 2021 (worldwide)

  1. Admission patterns and clinical management of rare diseases in 46 pediatric intensive care units across China: a multicenter survey. Frontiers in pediatrics, 2026
  2. Reimbursement status, access delays and prices of orphan drugs in France: a population-stratified analysis of indications approved between 2021 and 2024. Orphanet journal of rare diseases, 2026
  3. Regulatory Pathways and Pivotal Trial Characteristics of Medicines Designated under the European Medicines Agency's Priority Medicines Scheme Approved between 2018 and 2024. Pharmaceutical medicine, 2026
  4. Investigator-Initiated Trials as a Clinical Development Approach for Orphan Drugs Compared with Industry-Sponsored Trials in Japan. Therapeutic innovation & regulatory science, 2026
  5. Making trade-offs explicit: development and pilot of a Belgian MCDA framework for orphan drug appraisal. International journal of technology assessment in health care, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Orphan Drugs in context

Australia compared

  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[1]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 3rd highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Orphan Drugs market in Australia?
Placeholder estimate: about $3.17 Bn in 2025, rising to about $8.92 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Orphan Drugs market in Australia growing?
Placeholder estimate: about 12.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Orphan Drugs market report cover?
The report splits the market by drug type (Biologics, Small Molecules, Gene and Cell Therapies), therapy area (Oncology, Hematology, Neurology, Metabolic and more) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Orphan Drugs market?
Key players include Novartis AG, Sanofi, Roche, Takeda Pharmaceutical Company Ltd, Vertex Pharmaceuticals and Alexion (AstraZeneca).
What is driving the Orphan Drugs market?
Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the orphan Drugs market. More countries now have national rare disease plans.
Who regulates Orphan Drugs in Australia?
Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How much research is published on Orphan Drugs?
PubMed lists 435 papers on Orphan Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Orphan Drugs in Australia? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Patient Support Programmes: Helping Patients Stay on TreatmentWHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient… Biologic Safety Testing: The Quiet Backbone of Drug MakingEvery vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches… Cell-Based Immunotherapy: Promise and PriceThe first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Australia

See all
Same topic, other categories

Related on rare diseases and biologics and biosimilars

See the topic